Novo Nordisk A/S (NYSE:NVO) has been given an average rating of “Hold” by the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $48.61.
Several equities analysts recently commented on NVO shares. Handelsbanken cut shares of Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price objective for the company. in a research note on Monday, February 4th. UBS Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Sunday, December 2nd. Pareto Securities raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, November 26th. Deutsche Bank reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, December 10th. Finally, Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $52.00 target price for the company in a research report on Wednesday, January 2nd.
A number of institutional investors have recently made changes to their positions in the business. Atwater Malick LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $3,082,000. Pinnacle Bank bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $40,000. Geode Capital Management LLC lifted its position in Novo Nordisk A/S by 8.3% during the fourth quarter. Geode Capital Management LLC now owns 39,942 shares of the company’s stock valued at $1,840,000 after purchasing an additional 3,060 shares during the last quarter. Princeton Global Asset Management LLC bought a new stake in Novo Nordisk A/S during the fourth quarter valued at approximately $55,000. Finally, Valley National Advisers Inc. lifted its position in Novo Nordisk A/S by 1,012.4% during the fourth quarter. Valley National Advisers Inc. now owns 10,245 shares of the company’s stock valued at $472,000 after purchasing an additional 9,324 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.
Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Friday, February 1st. The company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.03). The firm had revenue of $4.55 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. As a group, equities analysts forecast that Novo Nordisk A/S will post 2.55 EPS for the current year.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.